BIIBHealthcare · Drug Manufacturers - GeneralThe 35 Wall Street analysts covering Biogen, Inc. hold a median 12-month price target of $240 — +10.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Biogen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (32): The company has been issuing shares or taking on financing, diluting existing holders.
Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BIIB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +10.5% from it.
Of the 20 most recent actions, 9 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Sept 2026 | HSBC | Maintains | Reduce | $165 → $175 |
| 3 Sept 2026 | Piper Sandler | Reiterates | Overweight | $225 → $245 |
| 25 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 25 Aug 2026 | RBC Capital | Maintains | Outperform | $240 → $260 |
| 13 Aug 2026 | Wolfe Research | Upgrade | Outperform | $300 |
| 13 Aug 2026 | Wolfe Research | Upgrade | Outperform | — |
| 4 Aug 2026 | Mizuho | Maintains | Outperform | — |
| 4 Aug 2026 | Mizuho | Maintains | Outperform | $221 → $241 |
| 3 Aug 2026 | Citigroup | Maintains | Neutral | — |
| 3 Aug 2026 | Citigroup | Maintains | Neutral | $200 → $215 |
| 30 July 2026 | Canaccord Genuity | Maintains | Buy | $245 → $248 |
| 30 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 30 July 2026 | HC Wainwright & Co. | Maintains | Buy | $237 → $251 |
| 30 July 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 July 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 30 July 2026 | Morgan Stanley | Maintains | Equal-Weight | $222 → $231 |
| 30 July 2026 | RBC Capital | Maintains | Outperform | $242 → $240 |
| 30 July 2026 | RBC Capital | Maintains | Outperform | — |
| 30 July 2026 | TD Cowen | Maintains | Buy | $215 → $225 |
| 30 July 2026 | TD Cowen | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BIIB appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Biogen, Inc. returned +45.9% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 19% of US stocks
Cheaper than 39% of US stocks
Cheaper than 51% of US stocks
Cheaper than 32% of US stocks
Higher than 35% of US stocks
Higher than 4% of US stocks
Higher than 84% of US stocks
Higher than 84% of US stocks
Higher than 66% of US stocks
Higher than 53% of US stocks
Higher than 77% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Biogen, Inc. has a market value of $32.1B and an enterprise value of $39.2B.
Revenue in the twelve months to 30 June 2026: $10.0B. The latest quarter grew 3.4% year on year.
Net income over the same four quarters: $834.6M, a 8.3% net margin.
Diluted earnings per share, trailing twelve months: $5.65.
Free cash flow in the twelve months to 30 June 2026: $2.5B.
Trailing P/E: 38.6×; forward P/E: 13.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Biogen, Inc. employs 7,500 people — $1.3M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Biogen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Biogen executives said the company is focused on diversifying beyond its historical neurology concentration, advancing a broader late-stage pipeline and managing expenses as it seeks to return to growth.
Why it matters — A BIIB watcher would care because the company's shift beyond neurology and its late-stage pipeline are central to its stated strategy for returning to growth.
Biogen Inc. presented at the Wells Fargo 21st Annual Healthcare Conference, with a transcript of the event released by Seeking Alpha. The presentation covers the company's remarks at the conference.
Why it matters — BIIB watchers would care because the transcript provides insight into the company's stated position and messaging at a major healthcare investor conference.
Eli Lilly is expanding its neuroscience pipeline through strong growth and mergers and acquisitions, aiming to build neuroscience into a new long-term growth driver beyond its cardiometabolic therapies.
Why it matters — As a fellow neuroscience-focused company, Biogen could face increased competition if Lilly's expanded pipeline gains traction in that therapeutic space.
Stoke Therapeutics and Biogen presented long-term clinical data at the 16th European Epilepsy Congress showing that four-year results from Phase 1/2a open-label extension studies of zorevunersen, an investigational treatment for Dravet syndrome, demonstrated substantial and durable reductions in seizures and continued improvements in cognition and behavior when used alongside standard-of-care anti-seizure medicines.
Why it matters — The data support the disease-modifying potential of zorevunersen, a key investigational asset in Biogen's pipeline for Dravet syndrome.
Eisai and Biogen's LEQEMBI (lecanemab) subcutaneous formulation was approved in China as an initiation treatment for early Alzheimer's disease. It is described as the first and only anti-amyloid therapy in China enabling at-home administration.
Why it matters — China approval of the at-home subcutaneous formulation broadens the commercial availability and accessibility of a key Biogen-partnered Alzheimer's therapy in a major market.
The 35 Wall Street analysts covering Biogen, Inc. have a median 12-month price target of $240, with estimates ranging from $175 to $300. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 35 analysts covering Biogen, Inc., 23 rate it a Buy, 11 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Biogen, Inc. 75 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Biogen, Inc. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No one can know that. What the data says: the median 12-month target from 35 analysts implies +10.5% from the last close, and Ticker Nerd's factor model ranks Biogen, Inc. 75 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Biogen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BIIB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $175 to $300 over the next 12 months.
Biogen, Inc. returned +45.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Biogen Inc. is a biotechnology company focused on discovering, developing, and delivering therapies for serious neurological, neurodegenerative, and rare diseases.
The most recent item we track (MarketBeat, 12 Sept 2026): "Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology". Biogen executives said the company is focused on diversifying beyond its historical neurology concentration, advancing a broader late-stage pipeline and managing expenses as it seeks to return to growth.
Biogen Inc. is a biotechnology company focused on discovering, developing, and delivering therapies for serious neurological, neurodegenerative, and rare diseases. Biogen’s current portfolio includes treatments for multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis, and Friedreich’s ataxia, along with therapies and biosimilars used in specialized immunology and related areas. The company also advances medicines through its research and development programs, with a strong emphasis on neuroscience and immunology. Based in Cambridge, Massachusetts, Biogen serves patients and healthcare providers across multiple global markets through its commercial products and collaborations. Its role in the financial market is shaped by its concentration in specialty biopharmaceuticals, recurring demand for chronic-disease treatments, and continued activity in pipeline development and product commercialization.
CEO Mr. Christopher A. Viehbacher · 7,500 employees · United States · https://www.biogen.com
